

SUMO-2 Antibody - With BSA and Azide

Mouse Monoclonal Antibody [Clone SUMO2/1199]
Catalog # AH12320

Specification

SUMO-2 Antibody - With BSA and Azide - Product Information

Application IHC, IF, FC
Primary Accession P55854
Other Accession 6613, 474005
Reactivity Human, Rat
Host Mouse
Clonality Monoclonal

Isotype Mouse / IgG1, kappa Calculated MW 11-13kDa KDa

SUMO-2 Antibody - With BSA and Azide - Additional Information

Gene ID 6612

Other Names

Small ubiquitin-related modifier 3, SUMO-3, SMT3 homolog 1 {ECO:0000312|HGNC:HGNC:11124}, SUMO-2, Ubiquitin-like protein SMT3A, Smt3A, SUMO3 (HGNC:11124)

Application Note

IHC~~1:100~500<br \> <span class
="dilution IF">IF~~1:50~200<br \> FC~~1:10~50

Storage

Store at 2 to 8°C. Antibody is stable for 24 months.

Precautions

SUMO-2 Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

SUMO-2 Antibody - With BSA and Azide - Protein Information

Name SUMO3 (HGNC:11124)

Function

Ubiquitin-like protein which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Does not seem to be involved in protein degradation and may function as an antagonist of ubiquitin in the degradation process. Plays a role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4 (PubMed:<a href="http://www.uniprot.org/citations/11451954"



 $target="_blank">11451954, PubMed:18538659, PubMed:21965678). Plays a role in the regulation of sumoylation status of SETX (PubMed:24105744).$

Cellular Location

Cytoplasm. Nucleus. Nucleus, PML body

Tissue Location


Expressed predominantly in liver.

SUMO-2 Antibody - With BSA and Azide - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

SUMO-2 Antibody - With BSA and Azide - Images



Formalin-fixed, paraffin-embedded human Tonsil stained with SUMO-2 Monoclonal Antibody (SUMO2/1199)







Formalin-fixed, paraffin-embedded human Tonsil stained with SUMO-2 Monoclonal Antibody (SUMO2/1199)



Formalin-fixed, paraffin-embedded human Ovarian Carcinoma stained with SUMO-2 Monoclonal Antibody (SUMO2/1199)




Formalin-fixed, paraffin-embedded human Testicular Carcinoma stained with SUMO-2 Monoclonal Antibody (SUMO2/1199)



Formalin-fixed, paraffin-embedded Rat Ovary stained with SUMO-2 Monoclonal Antibody (SUMO2/1199)





Formalin-fixed, paraffin-embedded Rat Heart stained with SUMO-2 Monoclonal Antibody (SUMO2/1199)

SUMO-2 Antibody - With BSA and Azide - Background

The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease.